作者
Behnood Bikdeli, Mahesh V Madhavan, Aakriti Gupta, David Jimenez, John R Burton, Caroline Der Nigoghossian, Taylor Chuich, Shayan Nabavi Nouri, Isaac Dreyfus, Elissa Driggin, Sanjum Sethi, Kartik Sehgal, Saurav Chatterjee, Walter Ageno, Mohammad Madjid, Yutao Guo, Liang V Tang, Yu Hu, Laurent Bertoletti, Jay Giri, Mary Cushman, Isabelle Quéré, Evangelos P Dimakakos, C Michael Gibson, Giuseppe Lippi, Emmanuel J Favaloro, Jawed Fareed, Alfonso J Tafur, Dominic P Francese, Jaya Batra, Anna Falanga, Kevin J Clerkin, Nir Uriel, Ajay Kirtane, Claire McLintock, Beverley J Hunt, Alex C Spyropoulos, Geoffrey D Barnes, John W Eikelboom, Ido Weinberg, Sam Schulman, Marc Carrier, Gregory Piazza, Joshua A Beckman, Martin B Leon, Gregg W Stone, Stephan Rosenkranz, Samuel Z Goldhaber, Sahil A Parikh, Manuel Monreal, Harlan M Krumholz, Stavros V Konstantinides, Jeffrey I Weitz, Gregory YH Lip
发表日期
2020/5/30
来源
Thrombosis and Haemostasis
出版商
Georg Thieme Verlag KG
简介
Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific …
学术搜索中的文章
B Bikdeli, MV Madhavan, A Gupta, D Jimenez… - Thrombosis and haemostasis, 2020